In-House Counsel

Draft guidelines regarding excessive pricing of patented medicines released

Wednesday, November 23, 2022 @ 1:35 PM | By Nathaniel Lipkus and Yael Mansour

Federal price controls for patented medicines have been part of Canadian law for approximately 35 years. The Patented Medicine Prices Review Board’s (PMPRB) mandate is to prevent excessive pricing of patented...

To view the full article, Click Here to Subscribe
or sign up for a 14-day FREE Trial

Already a subscriber? Click here to sign in

Featured

Chief Justice of British Columbia Robert Bauman

Ottawa ‘saves’ millions by making tardy judicial appointments; average delay 11 months in 2023

Latest

Business Canada signs Ukraine free-trade deal, sanctions illegal transfer of Ukrainian kids to Russia

Business Federal Court dismisses application to withhold information sought under Access to Information Act

Civil Litigation Court denies developer’s appeal to not pay road improvement costs

Civil Litigation Court dismisses extension to appeal where unit owner owed over $300K in levies

Personal Injury Judge erred in refusing to grant leave to amend statement of claim against Bayer Inc., court rules